IPSWICH, Mass., Jan. 7 -- New England Biolabs (NEB) has introduced Lemo21(DE3) Competent E. coli, a tunable T7 expressionstrain optimized for the expression of difficult constructs, including membrane proteins, toxic proteins and proteins prone to insoluble expression. A derivative of BL21(DE3), Lemo21(DE3) offers the host features of this commonly used expression strain,
Lemo21(DE3) is the first commercial product from NEB based on the Lemo System™, a technology developed by Xbrane Bioscience, a company originating from the Center for Biomembrane Research at Stockholm University. NEB and Xbrane Bioscience recently announced an agreement in which NEB would commercialize products based on the Lemo System through its international distribution network. Additionally, the technology is available for licensing by both companies.
Lemo 21(DE3) Competent E. coli is being launched at the Pep Talk 2010 Protein Expression Conference, January 12-15, 2010 in San Diego, CA.
For more information, visit www.neb.com.
SOURCE New England Biolabs
Subscribe to our Free Newsletters!
Cyanosis is the bluish or purplish discoloration of the skin and mucus membranes due to lack of ...
Find out about travel shots or vaccination before you travel to your destination country. Travel ...
Hay fever is caused by allergy to pollen and is characterized by runny or blocked nose, sneezing, ...View All